Therapeutic vaccination targeting self-molecules could provide a cost-efficient alternative to monoclonal antibody-based therapies for cancer and various inflammatory diseases. However, development of cancer vaccines targeting self-molecules has proven difficult. One complicating factor is that tumour cells have developed strategies to escape recognition by the immune system. Antigens specifically expressed by the tumour vasculature can therefore provide alternative targets. The present mini-review highlights potential target molecules associated with tumour angiogenesis and the approaches made to direct an immune response against them. Furthermore, the requirements on a vaccine targeting self-molecules, in contrast with those directed against virus or bacteria, are discussed.
Skip Nav Destination
Article navigation
December 2014
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
Conference Article|
November 17 2014
Therapeutic vaccination targeting the tumour vasculature
Anna-Karin Olsson
Anna-Karin Olsson
1
*Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Biomedical Center, Box 582, SE-75123 Uppsala, Sweden
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
October 13 2014
Online ISSN: 1470-8752
Print ISSN: 0300-5127
© The Authors Journal compilation © 2014 Biochemical Society
2014
Biochem Soc Trans (2014) 42 (6): 1653–1657.
Article history
Received:
October 13 2014
Citation
Anna-Karin Olsson; Therapeutic vaccination targeting the tumour vasculature. Biochem Soc Trans 1 December 2014; 42 (6): 1653–1657. doi: https://doi.org/10.1042/BST20140196
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.